Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:
EDISON Oncology ABCs – Vaccines: Niche no longer
Mendus CMO Jeroen Rovers will participate in an expert panel webcast organized by Edison Group. Further details will be provided on the Mendus website in due time.
Leipzig, Germany, October 24-26, 2022
Mendus CEO Erik Manting and Director Business Development Céline Hechard will participate in the partnering conference.
European Society of Gynaecological Oncology 23rd Annual Conference
Berlin, Germany, October 27-30, 2022
Director Research Satwinder Kaur Singh to attend, initial data from the ALISON Phase I trial in ovarian cancer to be presented together with Mendus’ collaboration partner, the Department of Obstetrics and Gynaecology of the University Medical Centre Groningen, The Netherlands.
FOR MORE INFORMATION, PLEASE CONTACT:
Chief Executive Officer
LifeSci Advisors, LLC
Telephone: + 1 212-915-2577
Telephone: +49 160 9352 9951
ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/